Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Biotica extends license to Amyris for polyketide engineering technology


CAMBRIDGE, UK (16 February 2011) – Biotica Technology Ltd. announces today that it has signed an agreement with Amyris, Inc. (NASDAQ: AMRS) under which Amyris obtains a non-exclusive license to Biotica’s polyketide engineering technology within its areas of business, including biofuels. Financial terms were not disclosed.

“Amyris is a leader in renewable specialty chemicals and transportation fuels and an ideal partner to use our polyketide engineering technology” commented Edward Hodgkin, Chief Executive Officer of Biotica.

“Biotica holds a dominant IP position in polyketide engineering technology, and we are delighted to be able to use their methods in our research” added Neil Renninger, Chief Technology Officer of Amyris.

In July 2010 Biotica acquired a portfolio of technology IP from Bristol-Myers Squibb Company (NYSE: BMY), including IP formerly controlled by Kosan Biosciences. The acquired IP, combined with Biotica’s substantial IP portfolio, gave Biotica a leading position in polyketide engineering. Amyris now has access to that technology IP. Biotica will continue to focus on polyketide therapeutics, taking advantage of its IP position to exploit the enormous potential of the polyketide opportunity.

--ends--
Notes to editors:

About Biotica
Biotica is a privately-held biotechnology company that discovers and develops polyketide therapeutics. It has a growing pipeline of novel therapeutic programmes supported by clinical validation. These include nPT-mTOR (unique mTOR inhibitors partnered with Pfizer), nPT-CyP (cyclophilin inhibitors for HCV) and nPT-ery (anti-inflammatory erythromycin analogues partnered with GlaxoSmithKline). All of Biotica’s projects employ its proprietary novoPT™ technology, which enables it to select from the many known polyketides with biological activity and make a range of derivatives that are either difficult or impossible to make by medicinal chemistry methods. For additional information visit www.biotica.com.

For more information please contact:

Edward Hodgkin, CEO, Biotica
Tel: +44 (0) 1799 532 923

Dr Lynne Trowbridge, Daniel Gooch, College Hill
Tel: +44 (0) 20 7866 7866


Publisher Contact Information:

Biotica Technology Limited
+44 (0) 1799 532 923
-

Company profile of Biotica Technology Limited
Past press releases of Biotica Technology Limited.

Data


25,099
Tech investments
From our Online Data Service
16,240
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 7€6.3MNanotechnology
Dec 7€21.1MInternet commerce
Dec 7€4.8MInternet commerce
Dec 7€1.8MInternet commerce
Dec 6N/AInternet commerce
Dec 6€26.0MBusiness applications
Dec 6€5.6MMedical devices

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom





About usContact usLegal Information
Copyright © 1999-2018
Emerging Technology Research Europe Inc. All rights reserved.